검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Blood samples (Blood samples) Assistance Publique Hopitaux De Ma…·Head and Neck Cancer ORR 13%·t½ 36.6 h |
|---|---|
Overview Program | Blood samples |
Overview Company | Assistance Publique Hopitaux De Marseille |
Overview Modality | ANTIBODY |
Overview Target | Head and Neck Cancer |
Overview Indication | Head and Neck Cancer |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
MoA Mechanism | targeting chimeric antigen receptor |
MoA Biomarker | biomarker phenotypic characterization of rare cells, single rare cell isolation for molecular analysis, and f |
PK/PD Half-life | 36.6 h |
PK/PD Species | Pig |
PK/PD Animal (cat.) | In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Pig |
Toxicology Animal (cat.) | In vitro |
Toxicology Major finding | Pharmacogenomic screening strategy and indicative screening efficiency for antithyroid drug-induced agranulocytosis in the Southern Han Chinese.. Antithyroid drug-induced agranulocytosis (ATDIA) is a life-threatening adverse drug reaction with strong population-specific genetic predispositions. This study aimed to develop a pharmacogenomic risk-stratification model and to evaluate the indicative s… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 13% |
Clinical ORR | 13% |
Clinical Result source | ClinicalTrials.gov NCT00068341 |
Clinical Data Tier / Score | A · 26 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Blood samples (Blood samples) Assistance Publique Hopitaux De Ma…·Head and Neck Cancer ORR 13%·t½ 36.6 h |
|---|---|
Overview Program | Blood samples |
Overview Company | Assistance Publique Hopitaux De Marseille |
Overview Modality | ANTIBODY |
Overview Target | Head and Neck Cancer |
Overview Indication | Head and Neck Cancer |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
MoA Mechanism | targeting chimeric antigen receptor |
MoA Biomarker | biomarker phenotypic characterization of rare cells, single rare cell isolation for molecular analysis, and f |
PK/PD Half-life | 36.6 h |
PK/PD Species | Pig |
PK/PD Animal (cat.) | In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Pig |
Toxicology Animal (cat.) | In vitro |
Toxicology Major finding | Pharmacogenomic screening strategy and indicative screening efficiency for antithyroid drug-induced agranulocytosis in the Southern Han Chinese.. Antithyroid drug-induced agranulocytosis (ATDIA) is a life-threatening adverse drug reaction with strong population-specific genetic predispositions. This study aimed to develop a pharmacogenomic risk-stratification model and to evaluate the indicative s… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 13% |
Clinical ORR | 13% |
Clinical Result source | ClinicalTrials.gov NCT00068341 |
Clinical Data Tier / Score | A · 26 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
추천 비교
추천 비교